Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-308 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| IV ABT-308 in asthmatics | EXPERIMENTAL | ABT-308 single escalating doses in mild to moderate asthmatics |
| SC ABT-308 in asthmatics | EXPERIMENTAL | ABT-308 multiple SQ doses in mild to moderate asthmatics |
| IV ABT-308 in healthy volunteers | EXPERIMENTAL | ABT-308 single escalating IV doses in healthy volunteers |
| Name | Type | Description |
|---|---|---|
| ABT-308 | DRUG | Single IV doses |
| Placebo | DRUG | Single IV dose |
Inclusion Criteria: * Healthy volunteers: 1. A condition of good health based upon the results of medical history, physical examination, vital signs, laboratory profile and ECG. 2. BMI 18 to 29, inclusive. * Mild asthma patients: 1. Diagnosis of well-controlled, mild to moderate asthma by G...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
ABT-308 is an investigational small molecule being developed for the treatment of asthma. It is currently in Phase 1 clinical development, meaning it is still being studied and has not been approved for use.
ABT-308 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is in Phase 1 clinical development for asthma.
ABT-308 is in Phase 1 clinical development. It is an investigational drug for asthma and has not been approved by regulatory authorities. The drug is still being studied for safety and tolerability.
ABT-308 has one completed clinical trial, NCT00986037, titled 'Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma.' This Phase 1 study enrolled 47 participants and included healthy volunteers as well as subjects with asthma.
Yes, ABT-308 is a small molecule drug. It is being developed as an oral or systemic treatment for asthma, though the specific route of administration has not been disclosed.